Shaw, Executive Chairperson of Biocon & Biocon Biologics, said the pharma industry faces long 'lab-to-market' timelines, high ...

India trade relations prompted foreign investors to flee companies exposed to tariff risks, but retail investors significantly increased their buying in these stocks during the April-June period.

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive ...

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite ...

Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to ...

The biopharma company's stock fell as much as 3.60 per cent during the day to ₹331 per share, the lowest level since June 6 ...

Revenue from operations, however, grew 1 4.8% YoY to ₹3,942 crore, against ₹3,433 crore in the year-ago period. This figure ...

Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit ...

Biocon's consolidated net profit plummeted by 95% to Rs 31 crore in the June quarter, with total revenue declining to Rs ...

Trading at Rs 367.85, Biocon shows a positive move in today's early trading session, with the stock included in the Nifty Midcap 150 index.

Biocon Ltd. reported a 95% fall in net profit for the first quarter of financial year 2026. The pharma company reported a ...